Relievant Medsystems, Inc.
Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2006
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Welcome
We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2
Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.
The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.
Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.
About Us
After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device industry’s first successful large-scale Level l, randomized sham-controlled trial for chronic vertebrogenic low back pain. Relievant then sponsored the INTRACEPT Study — a Level l, prospective, randomized clinical study comparing the Intracept Procedure to conservative care for patients with chronic vertebrogenic low back pain.
The INTRACEPT Study was initiated in 2017, and enrollment was stopped for superiority of the primary and all secondary endpoints in January 2019. With significant treatment effects demonstrated, results were published in June of that year.
In 2019, 24 month results from the SMART trial were published – followed in 2020 by a publication showing previously published outcomes were durable through 5 years.